SCHEMBL1633446

SCHEMBL1633446

COc1ccc(Oc2cccc3cnc(Nc4ccc(S(N)(=O)=O)cc4)nc23)cc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 6/20 0.56
CA1 P00915 5/20 0.50
CA2 P00918 5/20 0.50
CA9 Q16790 4/20 0.50
CA12 O43570 2/20 0.50
RORC P51449 1/20 0.50
EGFR P00533 1/20 0.49
ERBB3 P21860 1/20 0.49
CDK2 P24941 2/20 0.48
JAK2 O60674 1/20 0.47
JAK1 P23458 1/20 0.47
TYK2 P29597 1/20 0.47
JAK3 P52333 1/20 0.47
STK4 Q13043 2/20 0.47
BRD4 O60885 1/20 0.47
MEN1 O00255 1/20 0.45
MAPT P10636 1/20 0.45
KMT2A Q03164 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1633814 0.92 EGFR (0.55) IKBKBCA1CA2CA9CA12
SCHEMBL1634182 0.90 CA1 (0.60) IKBKBCA1CA2CA9CA12
SCHEMBL1632825 0.90 IKBKB (0.48) IKBKBCA1CA2CA9CA12
SCHEMBL1633821 0.88 STK4 (0.52) IKBKBCA1CA2CA9EGFR
SCHEMBL1634190 0.87 IKBKB (0.53) IKBKBCA1CA2CA9CA12
SCHEMBL1633962 0.85 IKBKB (0.51) IKBKBCA1CA2CA9CA12
SCHEMBL1632432 0.82 CYP1A2 (0.48) IKBKBCA1CA2CA9CA12
SCHEMBL1634183 0.82 EGFR (0.52) IKBKBCA1CA2CA9CA12
SCHEMBL1633262 0.82 IKBKB (0.49) IKBKBCA1CA2CA9CA12
SCHEMBL1632814 0.81 CDK2 (0.52) IKBKBCA1CA2CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed